During the 2022 session of “two meetings”, rare diseases have been cited as one of the focus in healthcare in Prime Minister working report2. It is an important recognition of the severity of the issue and the need to find practical solutions. This article summarizes the situation of drugs against rare diseases in China and the progress already done. Moving forward, it suggests upgrading their positioning in the healthcare strategy in order to solve an important social issue and bring more steam into innovation in pharmaceutical.
|Publication status||Published - Mar 2022|
SourceChina Europe International Business School (CEIBS)